By Fineline Cube 
HepaBio Therapeutics announced that it has raised tens of millions of RMB in Series A strategic funding from TriApex. The two parties will engage in deep collaboration focused on new approach methodologies (NAMs), organoid technology platforms, and non‑clinical evaluation systems for innovative drugs, jointly promoting the construction of next‑generation drug R&D technology systems.
Financing Milestone
| Field | Detail |
|---|---|
| Company | HepaBio Therapeutics |
| Investor | TriApex (strategic investor) |
| Round | Series A strategic funding |
| Amount | Tens of millions of RMB |
| Date | 28 Aug 2026 |
| Use of Proceeds | Advancing organoid technology innovation, expanding disease models and drug R&D application scenarios |
Collaboration Framework & Technology Profile
- New Approach Methodologies (NAMs): Joint focus on next‑generation, human‑relevant testing methodologies for drug evaluation.
- Organoid Technology Platforms: HepaBio Therapeutics will continue to advance organoid technology innovation as the core of the collaboration.
- Non‑Clinical Evaluation Systems: Development of evaluation systems for innovative drugs, spanning earlier and more predictive preclinical assessment.
- Strategic Partnership: Beyond capital, TriApex and HepaBio Therapeutics will collaborate deeply to jointly build next‑generation drug R&D technology systems.
Growth Strategy – Application Expansion
| Focus Area | Direction |
|---|---|
| Organoid Technology Innovation | Continued advancement of platform capabilities |
| Disease Models | Expansion of organoid‑based disease model coverage |
| Drug R&D Scenarios | Broadening application scenarios across drug discovery and development |
| Industry Collaboration | Partnering to explore more precise, efficient, and human‑relevant drug discovery pathways |
Moving forward, HepaBio Therapeutics will continue to advance organoid technology innovation, expand disease models and drug R&D application scenarios, and collaborate with industry partners to explore more precise, efficient, and human‑relevant drug discovery and development pathways — positioning the company at the center of the shift toward NAMs‑based, human‑relevant preclinical models.
Market Impact & Outlook
- NAMs Momentum: The Series A investment from TriApex underscores growing industry demand for new approach methodologies and organoid‑based non‑clinical evaluation as alternatives and complements to animal testing.
- Strategic Alignment: The funding is paired with deep operational collaboration, aligning capital, technology, and commercial ecosystems around next‑generation drug R&D systems.
- Platform Scalability: Expansion of disease models and application scenarios broadens HepaBio Therapeutics‘ addressable markets across innovative drug development.
- Human‑Relevance Advantage: More precise, efficient, and human‑relevant drug discovery pathways address a persistent bottleneck in translational success rates for innovative drugs.
Forward‑Looking Statements — This brief contains forward‑looking statements regarding HepaBio Therapeutics‘ Series A strategic funding from TriApex and its future development of organoid technology platforms, new approach methodologies, and non‑clinical evaluation systems for innovative drugs. Such statements are based on current expectations and are subject to risks and uncertainties, including technology development, collaboration execution, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.-Fineline Info & Tech